Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6865 | 1358 | 41.0 | 91% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | TCF7L2 | Author keyword | 150 | 73% | 9% | 116 |
2 | CDKAL1 | Author keyword | 38 | 93% | 1% | 14 |
3 | SLC30A8 | Author keyword | 26 | 63% | 2% | 26 |
4 | MTNR1B | Author keyword | 23 | 79% | 1% | 15 |
5 | IGF2BP2 | Author keyword | 20 | 100% | 1% | 9 |
6 | TRANSCRIPTION FACTOR 7 LIKE 2 | Author keyword | 15 | 73% | 1% | 11 |
7 | TRANSCRIPTION FACTOR 7 LIKE 2 TCF7L2 | Author keyword | 12 | 86% | 0% | 6 |
8 | RS7903146 | Author keyword | 11 | 78% | 1% | 7 |
9 | CLIN SCI DIABET ENDOCRINOL | Address | 10 | 23% | 3% | 39 |
10 | KCNJ11 | Author keyword | 9 | 30% | 2% | 26 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | TCF7L2 | 150 | 73% | 9% | 116 | Search TCF7L2 | Search TCF7L2 |
2 | CDKAL1 | 38 | 93% | 1% | 14 | Search CDKAL1 | Search CDKAL1 |
3 | SLC30A8 | 26 | 63% | 2% | 26 | Search SLC30A8 | Search SLC30A8 |
4 | MTNR1B | 23 | 79% | 1% | 15 | Search MTNR1B | Search MTNR1B |
5 | IGF2BP2 | 20 | 100% | 1% | 9 | Search IGF2BP2 | Search IGF2BP2 |
6 | TRANSCRIPTION FACTOR 7 LIKE 2 | 15 | 73% | 1% | 11 | Search TRANSCRIPTION+FACTOR+7+LIKE+2 | Search TRANSCRIPTION+FACTOR+7+LIKE+2 |
7 | TRANSCRIPTION FACTOR 7 LIKE 2 TCF7L2 | 12 | 86% | 0% | 6 | Search TRANSCRIPTION+FACTOR+7+LIKE+2+TCF7L2 | Search TRANSCRIPTION+FACTOR+7+LIKE+2+TCF7L2 |
8 | RS7903146 | 11 | 78% | 1% | 7 | Search RS7903146 | Search RS7903146 |
9 | KCNJ11 | 9 | 30% | 2% | 26 | Search KCNJ11 | Search KCNJ11 |
10 | TCF7L2 GENE | 8 | 75% | 0% | 6 | Search TCF7L2+GENE | Search TCF7L2+GENE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CDKAL1 | 135 | 85% | 5% | 72 |
2 | TCF7L2 GENE | 79 | 75% | 4% | 57 |
3 | RISK LOCI | 75 | 31% | 15% | 206 |
4 | HHEX | 70 | 89% | 2% | 32 |
5 | TCF7L2 | 68 | 62% | 5% | 70 |
6 | IGF2BP2 | 60 | 80% | 3% | 37 |
7 | CDKN2A B | 49 | 82% | 2% | 28 |
8 | LARGE SCALE ASSOCIATION | 47 | 54% | 4% | 61 |
9 | TRANSCRIPTION FACTOR 7 LIKE 2 TCF7L2 GENE | 45 | 62% | 3% | 46 |
10 | MTNR1B | 38 | 63% | 3% | 38 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Rare and Common Genetic Events in Type 2 Diabetes: What Should Biologists Know? | 2015 | 2 | 95 | 59% |
SLC30A8 mutations in type 2 diabetes | 2015 | 2 | 42 | 52% |
GENOMIC MEDICINE Genomics, Type 2 Diabetes, and Obesity | 2010 | 296 | 73 | 45% |
Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here? | 2015 | 2 | 101 | 32% |
Genetics of type 2 diabetes: the GWAS era and future perspectives | 2011 | 54 | 79 | 76% |
The worldwide diabetes epidemic | 2012 | 69 | 26 | 42% |
Dorothy Hodgkin Lecture 2014 Understanding genes identified by genome-wide association studies for Type 2 diabetes | 2014 | 5 | 43 | 67% |
Susceptibility to type 2 diabetes mellitus-from genes to prevention | 2014 | 7 | 54 | 50% |
Genome wide association studies for diabetes: perspective on results and challenges | 2013 | 12 | 50 | 52% |
Genetic Susceptibility to Type 2 Diabetes and Obesity: Follow-Up of Findings from Genome-Wide Association Studies | 2014 | 7 | 125 | 49% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLIN SCI DIABET ENDOCRINOL | 10 | 23% | 2.9% | 39 |
2 | METAB DIS GRP | 5 | 33% | 1.0% | 13 |
3 | CHRON NONCOMMUNICABLE DIS CONTROL | 5 | 63% | 0.4% | 5 |
4 | ENDOCRINOL METAB KIDNEY DIS | 5 | 63% | 0.4% | 5 |
5 | DIABET GENET GRP | 4 | 75% | 0.2% | 3 |
6 | DISCIPLINE PUBL HLTH PREVENT MED | 3 | 100% | 0.2% | 3 |
7 | PREVENT MED ASSESSMENT | 3 | 100% | 0.2% | 3 |
8 | GENET EPIDEMIOL CLIN GRP | 3 | 24% | 0.9% | 12 |
9 | OXFORD HLTH | 3 | 24% | 0.8% | 11 |
10 | UMR 8199 | 3 | 23% | 0.9% | 12 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000262563 | CALPAIN 10//MED CELLULAR MOL PHYSIOL BIOSTAT//MOL GENET COMPLEX MONOGEN DISORDERS |
2 | 0.0000177857 | FTO//FTO GENE//FAT MASS AND OBESITY ASSOCIATED GENE |
3 | 0.0000109905 | MODY//MATURITY ONSET DIABETES OF THE YOUNG//MATURITY ONSET DIABETES OF THE YOUNG MODY |
4 | 0.0000106140 | RARE VARIANTS//GENETIC EPIDEMIOLOGY//RARE VARIANT ANALYSIS |
5 | 0.0000097500 | CHROMOSOME 9P21//PSMA6//9P21 |
6 | 0.0000095913 | ENPP1//PLASMA CELL MEMBRANE GLYCOPROTEIN 1//PC 1 |
7 | 0.0000092926 | PRO12ALA POLYMORPHISM//PRO12ALA//PPAR GAMMA 2 |
8 | 0.0000085543 | GLUCOSE EFFECTIVENESS//INTRAVENOUS GLUCOSE TOLERANCE TEST//MINIMAL MODEL |
9 | 0.0000066327 | NEONATAL DIABETES MELLITUS//NEONATAL DIABETES//WOLCOTT RALLISON SYNDROME |
10 | 0.0000058281 | APOL1//APOLIPOPROTEIN L1//APOLIPOPROTEIN L |